Importantly, CRISPR-induced knock-in of the c.35G>T mutation in trans (G12V) in the KRAS G12C lung cancer model NCI-H358_28D5, as well as the co-occurrence in cis in the KRAS G12F lung cancer model NCI-H2291, showed a strongly decreased sensitivity to the G12C-specific inhibitor AZ’8037 in vitro compared to the KRAS G12C lung cancer cell line. Here, KRAS is linked to lung carcinoma.